Five Prime Therapeutics to Present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology
21 sept. 2017 09h00 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Presents Preclinical Research Data on Novel B7-H4 Therapeutic Antibody at ESMO 2017 Congress
10 sept. 2017 11h45 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 at ESMO 2017 Congress
10 sept. 2017 04h45 HE
|
Five Prime Therapeutics, Inc.
Objective response rate of 48% and six-month disease control rate of 81% in patients at or below the maximum tolerated dose level; progression free survival of 7.4 monthsProgression-free survival...
Five Prime Announces Abstract with Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 at ESMO 2017 Congress
01 sept. 2017 16h05 HE
|
Five Prime Therapeutics, Inc.
Objective response rate of 48% and disease control rate of 100% in patients at or below the maximum tolerated dose levelMedian progression free survival of 7.4 months SOUTH SAN FRANCISCO, Calif.,...
Five Prime to Feature Two Oral Data Presentations at ESMO 2017 Congress
29 août 2017 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics Announces Addition of Bryan Irving, PhD, as Senior Vice President, Research
17 août 2017 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Announces Second Quarter 2017 Results and Provides Business Update
08 août 2017 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif. , Aug. 08, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics to Announce Second Quarter 2017 Financial Results and Host Conference Call on August 8
26 juil. 2017 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Clinical Safety Trial Evaluating FPA144 in Gastric Cancer in Japan in Preparation for Future Global Late-Stage Development
17 juil. 2017 16h10 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 17, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics Announces Lewis T. “Rusty” Williams Plans to Transition from CEO to Executive Chairman of the Board in 2018
21 juin 2017 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 21, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...